CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial. Knapper S, Dillon LW, Babu M, Thomas A, et al. Blood 2026;147:1048-1057.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Knapper S, Dillon LW, Babu M, Thomas A, et al. CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial. Blood 2026;147:1048-1057.
PMID: 41237344